[go: up one dir, main page]

AR041562A1 - Preparacion de liberacion controlada - Google Patents

Preparacion de liberacion controlada

Info

Publication number
AR041562A1
AR041562A1 ARP030103672A ARP030103672A AR041562A1 AR 041562 A1 AR041562 A1 AR 041562A1 AR P030103672 A ARP030103672 A AR P030103672A AR P030103672 A ARP030103672 A AR P030103672A AR 041562 A1 AR041562 A1 AR 041562A1
Authority
AR
Argentina
Prior art keywords
active ingredient
controlled
granule
controlled release
release
Prior art date
Application number
ARP030103672A
Other languages
English (en)
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32109465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR041562(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR041562A1 publication Critical patent/AR041562A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparación de liberación controlada en la cual la liberación del ingrediente activo lanzoprazol, entre otros, está controlada, la cual libera un ingrediente activo durante un período prolongado de tiempo permaneciendo o migrando lentamente por el tracto gastrointestinal, mediante el encapsulamiento de una tableta, gránulo o gránulo fino en los caules la liberación del ingrediente activo está controlada y un polímero formador de geles. Dicha tableta, gránulo o gránulo fino presenta una capa de recubrimiento de liberación controlada formada sobre una partícula central que contiene un ingrediente activo
ARP030103672A 2002-10-16 2003-10-09 Preparacion de liberacion controlada AR041562A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002301876 2002-10-16
JP2003066336 2003-03-12

Publications (1)

Publication Number Publication Date
AR041562A1 true AR041562A1 (es) 2005-05-18

Family

ID=32109465

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103672A AR041562A1 (es) 2002-10-16 2003-10-09 Preparacion de liberacion controlada

Country Status (27)

Country Link
US (7) US7790755B2 (es)
EP (3) EP2277510B1 (es)
JP (2) JP5330967B2 (es)
KR (3) KR101061750B1 (es)
CN (1) CN101884629B (es)
AR (1) AR041562A1 (es)
AU (2) AU2003272098B2 (es)
BR (2) BRPI0315142B8 (es)
CA (2) CA2499574C (es)
CR (2) CR10284A (es)
CY (1) CY1114599T1 (es)
DK (1) DK1553929T3 (es)
ES (1) ES2410812T5 (es)
IL (1) IL167447A (es)
MA (1) MA27456A1 (es)
MX (2) MX337937B (es)
MY (2) MY148805A (es)
NO (2) NO342002B1 (es)
NZ (2) NZ539353A (es)
OA (1) OA13143A (es)
PE (3) PE20050102A1 (es)
PL (2) PL219122B1 (es)
PT (1) PT1553929E (es)
SG (1) SG164281A1 (es)
SI (1) SI1553929T1 (es)
TW (2) TWI378794B (es)
WO (1) WO2004035020A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
CA2518780C (en) 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
WO2004082665A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
TW200606163A (en) 2004-04-22 2006-02-16 Eisai Co Ltd Imidazopyridine compound
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
CA2784881C (en) * 2005-02-25 2016-02-09 Takeda Pharmaceutical Company Limited Method for producing granules
WO2006093353A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
WO2007074108A1 (en) * 2005-12-28 2007-07-05 Basf Se Process for production of a water-absorbing material
US20090068263A1 (en) * 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (en) 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
CA2685745C (en) * 2007-05-08 2016-04-26 Dow Global Technologies Inc. Water dispersible polymer compositions
BRPI0818286A2 (pt) * 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
EP2573082A1 (en) 2007-12-31 2013-03-27 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
EA021792B1 (ru) 2008-03-11 2015-09-30 Такеда Фармасьютикал Компани Лимитед Твердый препарат, растворяющийся во рту
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
FR2938432B1 (fr) * 2008-11-14 2011-05-20 Debregeas Et Associes Pharma Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus
EP2501383A4 (en) * 2009-11-20 2013-06-26 Handa Pharmaceuticals Llc ORAL FORMULATION FOR DEXLANDSOPRAZOLE
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
CA2798081C (en) 2010-05-12 2024-02-13 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
HUE035763T2 (en) * 2010-06-08 2018-05-28 Kobe Gakuin Educational Found Method of producing coated particles and coated particles
WO2011159745A1 (en) 2010-06-16 2011-12-22 Takeda Pharmaceuticals North America, Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
US20120164233A1 (en) 2010-07-30 2012-06-28 Ranbaxy Laboratories Limited Pulsatile release pharmaceutical formulation of dexlansoprazole
US20120201886A1 (en) * 2010-07-30 2012-08-09 Micro Labs Limited Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
EP2661260A4 (en) * 2010-12-29 2014-05-14 Reddys Lab Ltd Dr BENZIMIDAZOLE FORMULATIONS WITH MODIFIED RELEASE
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
RU2590979C2 (ru) 2011-02-11 2016-07-10 ЗедЭкс ФАРМА, ЭлЭлСи Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
BR112014008744A2 (pt) 2011-10-21 2017-04-18 Takeda Pharmaceuticals Co preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer
US20130209592A1 (en) * 2012-02-13 2013-08-15 Steven C. Denstman Plant Extract Based Compositions and Methods For Treating Chronic Wounds
US20140330192A1 (en) * 2012-02-13 2014-11-06 The Ex Plant Company Dressing for application to a wound or burn
HRP20190210T1 (hr) 2013-04-23 2019-04-05 Zx Pharma, Llc Enterički premazani multipartikulatni pripravak s proteinskim podslojem
KR20160081322A (ko) 2014-12-31 2016-07-08 삼아제약 주식회사 양성자 펌프 억제제를 유효성분으로 포함하며 방출이 제어된 약제학적 조성물
KR101907116B1 (ko) * 2016-07-25 2018-10-11 한미약품 주식회사 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
CN107648231B (zh) * 2016-07-25 2021-07-16 江苏豪森药业集团有限公司 右兰索拉唑药物制剂
KR101877350B1 (ko) * 2016-10-28 2018-08-09 한미약품 주식회사 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
KR102727681B1 (ko) 2019-02-08 2024-11-07 주식회사유한양행 덱스란소프라졸 또는 이의 약학적으로 허용 가능한 염을 함유하는 안정한 경구투여용 약학 제제
CN111909044A (zh) * 2019-05-09 2020-11-10 南京爱德程医药科技有限公司 2-(烷基氨基)乙基苯甲酸酯类化合物的合成方法
CN114126408A (zh) * 2019-05-31 2022-03-01 戴纳立制药公司 嘧啶基氨基-吡唑化合物的改良释放配制品和治疗方法
US11839622B1 (en) 2020-01-15 2023-12-12 Randall Lewarchik Consumable nutraceutical composition
KR102471545B1 (ko) 2020-11-20 2022-11-29 서울대학교 산학협력단 덱스란소프라졸을 유효성분으로 포함하는 pH 의존성 타블렛-인-캡슐 복합제제 및 이의 제조방법
EP4304357A4 (en) * 2021-03-11 2025-01-22 In the Bowl Animal Health, Inc. Oral canine feed and methods for controlling tick infestations in a canine
AU2022232510A1 (en) * 2021-03-11 2023-09-21 In The Bowl Animal Health, Inc. Oral canine feed and methods for controlling flea infestations in a canine
KR102803742B1 (ko) 2022-07-25 2025-05-13 주식회사 와이에스생명과학 덱스란소프라졸 함유 정제
EP4356904A1 (en) * 2022-10-19 2024-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. A capsule comprising lansoprazole
KR20250167303A (ko) 2024-05-22 2025-12-01 한국유나이티드제약 주식회사 약제학적 제제

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
ZA854287B (en) 1984-06-16 1986-02-26 Byk Gulden Lomberg Chem Fab Dialkoxypyridines,process for their preparation,their use and medicaments containing them
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
KR890000387B1 (ko) 1984-09-24 1989-03-16 디 엎존 캄파니 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법
IL76839A (en) 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
SE8505112D0 (sv) 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
JPH07121859B2 (ja) 1986-03-18 1995-12-25 第一製薬株式会社 徐放性カプセル剤
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0643426B2 (ja) 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
JPH0674272B2 (ja) 1986-11-13 1994-09-21 エーザイ株式会社 ピリジン誘導体及びそれを含有する潰瘍治療剤
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0832625B2 (ja) 1987-01-29 1996-03-29 武田薬品工業株式会社 有核顆粒およびその製造法
JP2549119B2 (ja) 1987-05-30 1996-10-30 三省製薬株式会社 外用剤
JP2602518B2 (ja) * 1988-01-27 1997-04-23 エーザイ株式会社 被覆された胃酸分泌抑制剤含有組成物
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US4980172A (en) * 1989-05-12 1990-12-25 Fey Michael S Anti-smoking oral composition
FR2655266B1 (fr) 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US4965269A (en) 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5264223A (en) * 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ES2106818T3 (es) 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
WO1994006414A1 (fr) 1992-09-18 1994-03-31 Yamanouchi Pharmaceutical Co., Ltd. Preparation d'hydrogel a liberation prolongee
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
CZ289804B6 (cs) 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
WO1997012581A2 (en) * 1995-09-21 1997-04-10 Pharma Pass L.L.C. Novel composition containing an acid-labile omeprazole and process for its preparation
US5567144A (en) * 1995-10-05 1996-10-22 Desa International Inc. Hot surface ignition controller for fuel oil burner
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
PL188919B1 (pl) 1996-03-08 2005-05-31 Nycomed Danmark As Doustna, multijednostkowa kompozycja preparatu farmaceutycznego o modyfikowanym uwalnianiu oraz sposób wytwarzania jednostki dawkowania doustnej multijednostkowej kompozycji farmaceutycznej o modyfikowanym uwalnianiu
US6156340A (en) * 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
WO1998029095A2 (en) 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US6162463A (en) * 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
AU7375598A (en) * 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
DE19742711C1 (de) * 1997-09-26 1999-05-20 Intec Bielenberg Gmbh & Co Kg Vorrichtung zum Aufbringen von Klebepunkten auf ein Substrat
KR100387245B1 (ko) * 1997-10-17 2003-08-19 일양약품주식회사 유산균의안정화를위한미세장용성코팅과립
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AR018528A1 (es) 1997-12-12 2001-11-28 Expression Genetics Inc Mezcla polimerica biodegradable de micelas para transferencia genetica
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DE19801811B4 (de) * 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
WO1999038513A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. R-lansoprazole compositions and methods
DK173431B1 (da) * 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
DE69917618T2 (de) * 1998-04-03 2005-06-23 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
KR100627614B1 (ko) 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
DE19820529A1 (de) * 1998-05-08 1999-11-11 Lohmann Therapie Syst Lts Wirkstoff enthaltende orale und mucosale Zubereitung mit steuerbarer Wirkstofffreisetzung und ihre Verwendung
JP3746167B2 (ja) 1998-05-18 2006-02-15 武田薬品工業株式会社 医薬製剤
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
IT1301947B1 (it) * 1998-07-28 2000-07-20 Chiesi Farma Spa Formulazioni farmaceutiche di beclometasone dipropionato per iltrattamento di malattie infiammatorie croniche della mucosa
US7399485B1 (en) 1998-07-28 2008-07-15 Takeda Pharmaceutical Company Limited Rapidly Disintegrable solid preparation
US6093734A (en) 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
CA2507743C (en) 1998-08-12 2008-03-18 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
JP2000119181A (ja) 1998-10-06 2000-04-25 Kureha Chem Ind Co Ltd エスクレチン及びその誘導体の放出制御経口製剤
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US6511678B2 (en) * 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
IL131508A (en) * 1999-08-19 2006-12-10 David Cohen Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants
CA2380333A1 (en) 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
WO2001024780A2 (en) 1999-10-01 2001-04-12 Natco Pharma Limited Soft gel capsule resistant to gastric juices
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
KR100449797B1 (ko) 1999-11-02 2004-09-30 바실리어 파마슈티카 아게 Ｎ-치환된 카바모일옥시알킬-아졸리움 유도체
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
IT1318376B1 (it) 2000-03-07 2003-08-25 Pharmatec Internat S R L Forme solide orali a rilascio controllato contenenti mesalazina comeprincipio attivo.
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
WO2001080824A2 (en) 2000-04-19 2001-11-01 Eurand America, Inc. Dual mechanism timed release dosage forms for low dose drugs
CA2407208C (en) 2000-04-28 2010-08-17 Takeda Chemical Industries, Ltd. Process for producing optically active sulfoxide derivative
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
TWI232761B (en) * 2000-07-01 2005-05-21 Pharmaceutical Ind Tech & Dev Capsule preparation for oral administration and the preparation method thereof
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
EP1306375B1 (en) 2000-08-04 2006-10-11 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU2000265525A1 (en) 2000-08-29 2002-03-13 Mepha Ag Medicament for treating intestinal diseases
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
JP2002187890A (ja) 2000-10-12 2002-07-05 Takeda Chem Ind Ltd ベンズイミダゾール化合物、その製造法およびその用途
AU2001294228A1 (en) 2000-10-12 2002-04-22 Takeda Chemical Industries Ltd. Benzimidazole compounds, process for producing the same and use thereof
AU2001211213A1 (en) 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
CA2403670C (en) * 2001-01-31 2010-02-09 Rohm Gmbh & Co. Kg Multiparticulate drug form comprising at least two differently coated pellet forms
ITMI20010220A1 (it) 2001-02-05 2002-08-05 Valpharma Sa Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
US20050019399A1 (en) * 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
US20040248941A1 (en) 2001-09-25 2004-12-09 Keiji Kamiyama Benzimidazone compound, process for producing the same, and use thereof
WO2003103638A1 (en) 2002-06-07 2003-12-18 Geneva Pharmaceuticals, Inc. Stabilized pharmaceutical compositions containing benzimidazole compounds
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics

Also Published As

Publication number Publication date
US8784885B2 (en) 2014-07-22
EP1553929A2 (en) 2005-07-20
NO342002B1 (no) 2018-03-12
NZ552592A (en) 2007-06-29
CA2737851A1 (en) 2004-04-29
NO20180072A1 (no) 2005-05-13
NO343175B1 (no) 2018-11-26
AU2003272098B2 (en) 2009-12-10
TWI347202B (en) 2011-08-21
CY1114599T1 (el) 2016-10-05
US20100278911A1 (en) 2010-11-04
OA13143A (en) 2006-12-13
EP2277510B1 (en) 2018-12-26
PE20090076A1 (es) 2009-03-02
US20060013868A1 (en) 2006-01-19
KR20120034809A (ko) 2012-04-12
BR0315142B1 (pt) 2018-01-09
SI1553929T1 (sl) 2013-07-31
TWI378794B (en) 2012-12-11
CN101884629B (zh) 2013-08-21
US20100285120A1 (en) 2010-11-11
US20100272798A1 (en) 2010-10-28
MA27456A1 (fr) 2005-07-01
HK1080378A1 (en) 2006-04-28
KR101061750B1 (ko) 2011-09-02
US20140186448A1 (en) 2014-07-03
US20140186449A1 (en) 2014-07-03
US20160128945A1 (en) 2016-05-12
PL376222A1 (en) 2005-12-27
AU2003272098A1 (en) 2004-05-04
AU2009243408A1 (en) 2009-12-17
MXPA05003902A (es) 2005-06-22
EP2283827A1 (en) 2011-02-16
EP2277510A2 (en) 2011-01-26
ES2410812T3 (es) 2013-07-03
KR101401913B1 (ko) 2014-05-30
CA2737851C (en) 2013-04-30
EP1553929B1 (en) 2013-03-27
CR20110373A (es) 2011-08-24
PL219122B1 (pl) 2015-03-31
TW200502006A (en) 2005-01-16
MY148805A (en) 2013-05-31
JP2013155181A (ja) 2013-08-15
JP5330967B2 (ja) 2013-10-30
CN101884629A (zh) 2010-11-17
MY169471A (en) 2019-04-12
TW201125563A (en) 2011-08-01
CA2499574A1 (en) 2004-04-29
CA2499574C (en) 2011-07-05
PT1553929E (pt) 2013-04-23
SG164281A1 (en) 2010-09-29
BR122016030094B8 (pt) 2021-05-25
MX337937B (es) 2016-03-29
KR20100132082A (ko) 2010-12-16
WO2004035020A2 (en) 2004-04-29
EP1553929B2 (en) 2016-11-16
PE20110544A1 (es) 2011-08-25
DK1553929T3 (da) 2013-05-13
JP5746722B2 (ja) 2015-07-08
WO2004035020A3 (en) 2004-06-24
BR0315142A (pt) 2005-08-09
NO20052400L (no) 2005-05-13
EP2283827B1 (en) 2019-10-02
US7790755B2 (en) 2010-09-07
CR10284A (es) 2008-10-17
EP2277510A3 (en) 2012-02-01
ES2410812T5 (es) 2017-05-12
PE20050102A1 (es) 2005-04-05
US8722084B2 (en) 2014-05-13
BRPI0315142B8 (pt) 2021-05-25
AU2009243408B2 (en) 2012-01-19
JP2010077144A (ja) 2010-04-08
PL218177B1 (pl) 2014-10-31
NZ539353A (en) 2007-07-27
IL167447A (en) 2015-07-30
BR122016030094B1 (pt) 2020-06-23
KR20050072108A (ko) 2005-07-08

Similar Documents

Publication Publication Date Title
AR041562A1 (es) Preparacion de liberacion controlada
NO20016108D0 (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
NO20024919D0 (no) Hydrofil/lipofil polymer matriksdoseringsformulering
ES2166769T3 (es) Comprimido farmaceutico de liberacion controlada que presenta forma lenticular.
ATE477795T1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
JP2005501039A (ja) 可変放出割合を持つ薬剤制御放出システム
PE20090670A1 (es) Material compuesto polimerico con funcionalidad biocida
JP2013514837A5 (es)
CY1112582T1 (el) Διαδερμικη χορηγηση φεντανυλης
HRP20041152B1 (hr) Farmaceutske formulacije
BR0312347A (pt) Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato
DE60232496D1 (de) Tabletten, die in der mundhöhle schnell zerfallen
IL173078A0 (en) Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
DE60335557D1 (de) Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum
AR061860A1 (es) Prepracion farmaceutica para la administracion oral con liberacion controlada de ingrediente activo en el intestino delgado y metodo para su fabricacion
AR072492A1 (es) Dispositivo y administracion transdermica de estrogeno
ATE519510T1 (de) Antithrombogene und antirestenotische vaskuläre medizinprodukte
DE60205905D1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
CR7761A (es) Preparacion de liberacion controlada
ES2606399T3 (es) Formulación sólida de liberación controlada para administración oral en un sobre de dosis única y método de preparación de la misma
DE602006012310D1 (de) An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen
CY1108440T1 (el) Σκευασμα δοσολογιας υδροφιλης/λιποφιλης πολυμερους μητρας περιεχουσας ροπινιρολης

Legal Events

Date Code Title Description
FC Refusal